TY - GEN
T1 - Identification and quantification of thymosin β4 in human saliva and tears
AU - Badamchian, Mahnaz
AU - Damavandy, Ali A.
AU - Damavandy, Hadi
AU - Wadhwa, Sonal D.
AU - Katz, Barrett
AU - Goldstein, Allan L.
PY - 2007/9
Y1 - 2007/9
N2 - Thymosin β4 (Tβ4) is a ubiquitous, naturally occurring, 43-amino acid peptide that takes part in several biological activities including angiogenesis, inhibition of inflammation,wound healing, chemotaxis, and endothelial cell migration. Recent studies also indicate that Tβ4 accelerates corneal wound healing and downregulates several proinflamatory chemokines and cytokines. In this study, we sought to determine whether Tβ4 is naturally occurring in human tears and other human bodily fluids, such as saliva. Tear and saliva samples were analyzed by EIA to identify and quantify the amount of Tβ4 present. Around 10-20 samples were collected from each of three different age groups: 15-20, 25-35, and >50 years old with n = 30 and n = 60 for tears and saliva, respectively. Exclusion criteria included the use of any topical ophthalmic or topical oral medication and/or history of ocular or oral surgery within the past 6 months. Tears were collected from both eyes using Schirmer's strips. Saliva samples were collected in sterile tubes and were then centrifuged to remove solid particles. Tβ4 was found in tear and saliva samples in all age groups. The concentrations ranged from 0.5-7 μg/mL in tears and 0.2-3.6 μg/mL in saliva. In both fluids, Tβ4 concentration varied with age and appeared to peak at ages 25-35 years. Studies are in progress to determine if Tβ4 levels in saliva and tears demonstrate a circadian rhythm during a 24-h period, as well as to confirm that they vary with age and to explore if they vary with diseased states. This is the first study to report the presence of Tβ4 in human tears and saliva. This finding raises the possibility that Tβ4 acts as an endogenous agent contributing to the rapid healing of corneal and oralwounds. Considering that Tβ4 facilitates reepithelialization and modulates anti-inflammatory mediators, Tβ4 could potentially be used therapeutically in the treatment of (a) ocular surface disease and injury of eye and (b) various oral disorders, such as periodontal disease.
AB - Thymosin β4 (Tβ4) is a ubiquitous, naturally occurring, 43-amino acid peptide that takes part in several biological activities including angiogenesis, inhibition of inflammation,wound healing, chemotaxis, and endothelial cell migration. Recent studies also indicate that Tβ4 accelerates corneal wound healing and downregulates several proinflamatory chemokines and cytokines. In this study, we sought to determine whether Tβ4 is naturally occurring in human tears and other human bodily fluids, such as saliva. Tear and saliva samples were analyzed by EIA to identify and quantify the amount of Tβ4 present. Around 10-20 samples were collected from each of three different age groups: 15-20, 25-35, and >50 years old with n = 30 and n = 60 for tears and saliva, respectively. Exclusion criteria included the use of any topical ophthalmic or topical oral medication and/or history of ocular or oral surgery within the past 6 months. Tears were collected from both eyes using Schirmer's strips. Saliva samples were collected in sterile tubes and were then centrifuged to remove solid particles. Tβ4 was found in tear and saliva samples in all age groups. The concentrations ranged from 0.5-7 μg/mL in tears and 0.2-3.6 μg/mL in saliva. In both fluids, Tβ4 concentration varied with age and appeared to peak at ages 25-35 years. Studies are in progress to determine if Tβ4 levels in saliva and tears demonstrate a circadian rhythm during a 24-h period, as well as to confirm that they vary with age and to explore if they vary with diseased states. This is the first study to report the presence of Tβ4 in human tears and saliva. This finding raises the possibility that Tβ4 acts as an endogenous agent contributing to the rapid healing of corneal and oralwounds. Considering that Tβ4 facilitates reepithelialization and modulates anti-inflammatory mediators, Tβ4 could potentially be used therapeutically in the treatment of (a) ocular surface disease and injury of eye and (b) various oral disorders, such as periodontal disease.
KW - Human saliva
KW - Human tears
KW - Thymosin β
KW - Wound healing
UR - http://www.scopus.com/inward/record.url?scp=35349026855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35349026855&partnerID=8YFLogxK
U2 - 10.1196/annals.1415.046
DO - 10.1196/annals.1415.046
M3 - Conference contribution
C2 - 17600285
AN - SCOPUS:35349026855
SN - 1573317012
SN - 9781573317016
T3 - Annals of the New York Academy of Sciences
SP - 458
EP - 465
BT - Annals of the New York Academy of Sciences
PB - Blackwell Publishing Inc.
ER -